Drug Approval

China Approves First-in-Human Trial of Antengene’s ATG-201 for Autoimmune Diseases

Antengene Corporation Limited  ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, d...

 June 11, 2026 | News

XtalPi Lands $400M+ AI-Driven Drug Discovery Partnership for Metabolic GPCR Target

 XtalPi (2228.HK), a leading platform in artificial intelligence (AI) and robotics-driven drug discovery, announced a strategic partnership with a pro...

 June 11, 2026 | News

Harbour BioMed Secures China IND Acceptance for Novel Bispecific Cancer Therapy HBM7004

Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics i...

 June 11, 2026 | News

China Clears Adcentrx’s ADRX 0405 For Clinical Development In Advanced Solid Tumours

Follows initiation of Phase 1a/1b study in the U.S. Adcentrx intends to include clinical centers in China to broaden geographic repr...

 June 10, 2026 | News

Everest Medicines Acquires Greater China Rights to Presbyopia Therapy LNZ100

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, a...

 June 09, 2026 | News

Vcare PharmaTech Secures China Approval for Next Generation TRK Inhibitor Eratrectinib in NTRK Fusion Positive Solid Tumours

NTRK gene fusions have been identified as oncogenic drivers in adult and pediatric patients with pan-solid tumors. A fusion gene is typically formed by the...

 June 08, 2026 | News

Travere Secures Global Rights to Civorebrutinib in $1.14 Billion Kidney Disease Partnership with Everest Medicines

Civorebrutinib is an investigational oral, covalent reversible BTK inhibitor designed to provide differentiated efficacy, safety and convenience in immun...

 June 04, 2026 | News

Lilly Secures Global Rights To Hanmi's Sonefpeglutide In Potential $1.26 Billion Deal

Lilly licenses Hanmi's sonefpeglutide (LAPSGLP-2 analog) for multiple indications Hanmi Pharm. Co., Ltd. ("Hanmi") announced that they have entered i...

 June 02, 2026 | News

China Developed Anaesthetic Cipepofol Secures US FDA Approval, Marking Global Breakthrough

Cipepofol (CYPSEDO) Injection (hereinafter "Cipepofol"), a Class 1 innovative intravenous anesthetic independently developed by Haisco Pharmaceutical ...

 June 02, 2026 | News

Insilico Medicine And HLFM Launch AI Collaboration To Advance Human Longevity Science

Insilico Medicine ("Insilico", 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, and Human Life Foundation M...

 May 28, 2026 | News

Caliway Advances Global Phase 3 Programme For CBL 514 Following U.S. FDA IND Clearance

Asia-Pacific Phase 2 Study CBL-0206 Also Approved by Australia HREC and Taiwan TFDA, Accelerating Global Dual-Track Strategy ...

 May 26, 2026 | News

Scribe Therapeutics Gains Australian Clearance To Begin First Human Trial Of STX 1150 For Hypercholesterolemia

Scribe Therapeutics, Inc. (Scribe), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to exte...

 May 26, 2026 | News

Nuance Pharma Secures NMPA Clearance For Pivotal Actair® Allergy Trial In China

NMPA Approval Marks Key Milestone in Advancing House Dust Mite Allergy Immunotherapy to Chinese Patients Nuance Pharma announced that the National Medical...

 May 25, 2026 | News

AbbVie Receives Positive CHMP Opinion For MAVIRET In Acute Hepatitis C Treatment

The positive opinion is supported by data from the Phase 3 M20-350 study evaluating the safety and efficacy of MAVIRET® in a...

 May 25, 2026 | News


News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close